18.1-Statement: Existing evidence supports the use of SGLT2-inhibitors (SGLT2i) in adults with proteinuria and CKD and this benefit is likely to apply to individuals with AS. (Grade D, expert opinion). This evidence concerns the gene SLC5A2 and chronic kidney disease.